Literature DB >> 19364306

A report of outcomes after orthotopic liver transplant with allografts from heparin antibody-positive donors.

Thomas A Aloia1, John A Goss.   

Abstract

Heparin-induced thrombocytopenia (HIT) is an immune-mediated condition associated with thrombocytopenia and thrombotic complications. The condition is increasingly recognized in hospitalized patients including severely injured trauma patients. Because these patients may eventually be considered for organ donation, management of the HIT screenpositive donor has become an important issue in transplant surgery. We describe the recent management of 2 liver allograft donors with relative thrombocytopenia and positive HIT antibody screens. In both cases, systemic anticoagulation at the organ recovery operation was accomplished with argatroban, a synthetic thrombin inhibitor. This management strategy resulted in successful transplants for 7 recipients (1 heart, 2 liver, 4 kidney). Neither of the liver recipients demonstrated signs or symptoms of HIT, and neither had any postoperative thrombotic complications. Based on this experience, a treatment algorithm for managing HIT-positive donors is proposed. In addition, the pathophysiology of HIT and various testing modalities for the disorder are discussed.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19364306

Source DB:  PubMed          Journal:  Exp Clin Transplant        ISSN: 1304-0855            Impact factor:   0.945


  2 in total

Review 1.  Successful preemptive renal retransplantation in a patient with previous acute graft loss secondary to HIT type II: a case report and review of literature.

Authors:  Mahvish Muzaffar; Xin Li; Shobha Ratnam
Journal:  Int Urol Nephrol       Date:  2011-03-20       Impact factor: 2.370

2.  Successful liver transplantation in a patient with splanchnic vein thrombosis and pulmonary embolism due to polycythemia vera with Jak2v617f mutation and heparin-induced thrombocytopenia.

Authors:  Emanuela Biagioni; Paola Pedrazzi; Marco Marietta; Fabrizio Di Benedetto; Erica Villa; Mario Luppi; Massimo Girardis
Journal:  J Thromb Thrombolysis       Date:  2013-10       Impact factor: 2.300

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.